Streetbeat News

Revenues

UHS

Analysts have provided mixed ratings for Universal Health Services (NYSE:UHS) over the past three months, with a trend towards more bullish perspectives. The average 12-month price target has increased by 12.32% to $233.62. UHS has shown strong financial performance with a 10.13% revenue growth rate, a 7.4% net margin, and a debt-to-equity ratio of 0.77.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 9:00 pm

TTWO

Analysts have varied opinions on Take-Two Interactive (NASDAQ:TTWO), with 11 ratings ranging from bullish to bearish. The average 12-month price target is $191.73, slightly up from $190.56. Recent analyst actions include both upgrades and downgrades, reflecting mixed sentiments. Financially, Take-Two shows revenue growth but struggles with profitability, as indicated by a negative net margin and ROA.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 9:00 pm

BLMN

Bloomin Brands (NASDAQ:BLMN) has seen a range of analyst ratings over the past three months, with a shift towards more neutral and somewhat bullish perspectives. The average 12-month price target has decreased by 21.16% to $19.71. Analysts have lowered their ratings and price targets due to market conditions and company performance. Bloomin Brands faces challenges with declining revenue growth, low net margins, and high debt levels, but shows strong return on equity.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 9:00 pm

WT

Analysts have shown a positive shift in sentiment towards WisdomTree (NYSE:WT) with recent upgrades in ratings and price targets. The average 12-month price target has increased to $13.5, indicating a potential upside. WisdomTree has demonstrated strong revenue growth and financial health, though it faces challenges in net margin.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 9:00 pm

JHG

Analysts have provided mixed evaluations for Janus Henderson Group (NYSE:JHG) over the past three months, with most ratings being indifferent. The average 12-month price target has increased to $38.33, with a high of $42.00 and a low of $37.00. Analysts have raised their price targets, reflecting a positive outlook on the company's recent performance, including a 13.92% revenue growth rate. However, challenges remain in profitability and return on equity.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 9:00 pm

ACM

Analysts have varied ratings for AECOM (NYSE:ACM), with recent upgrades in price targets and ratings. The average 12-month price target increased to $110.88, with a high of $128.00. AECOM's financials show strong revenue growth but challenges in net margin and debt management.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 9:00 pm

VBTX

Veritex Holdings reported Q3 2024 earnings per share of $0.59, surpassing the analyst estimate of $0.55. The company's sales reached $113.168 million, exceeding the expected $110.240 million and marking a 3.79% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 8:49 pm

RNST

Renasant (NYSE:RNST) reported Q3 2024 earnings per share of $0.70, surpassing the analyst estimate of $0.63. Despite a year-over-year EPS decline, sales increased significantly to $220.297 million, beating expectations by 26.99%.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 8:48 pm

ENPH

Enphase Energy reported Q3 earnings that missed analyst expectations, with revenue of $380.9 million and adjusted earnings of 65 cents per share. U.S. revenue increased by 43% due to higher shipments, while European revenue fell by 15% due to softening demand. The company shipped 172.9 MWh of IQ batteries and 1,176,000 microinverters. Enphase ended the quarter with $1.77 billion in cash and expects Q4 revenue between $360 million and $400 million.

Portfolio Pulse from Adam Eckert

October 22, 2024 | 8:46 pm

CCHWF

CURLF

A recent poll indicates that 50% of Utahns support the legalization of recreational marijuana, showing a shift in public opinion. Utah's cannabis market, currently limited by strict regulations, presents significant potential for investors if laws change. Companies like Curaleaf and Columbia Care are active in Utah's medical cannabis market.

Portfolio Pulse from Nicolás Jose Rodriguez

October 22, 2024 | 8:43 pm